Item 8.01. Other Events.

The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Theravance Biopharma, Inc. (the "Company") is announcing that it has voluntarily discontinued its Phase 2 study of izencitinib (gut-selective oral pan-JAK inhibitor for inflammatory intestinal diseases) in Crohn's disease (Study 0173). The Company's decision was made following the planned review of trial data by the independent data monitoring committee who determined that, while there are no safety concerns, there are concerns about the ongoing benefit-risk of continuing the trial, and the committee recommended the sponsor discontinue the study. The Company has made the decision to discontinue the study.

© Edgar Online, source Glimpses